Dr. Reddy's Laboratories Limited (DRREDDY) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Total Revenue Chart for Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited (DRREDDY) revenue for FY2026 was INR 335.9B, a 3.2% change from FY2025. Dr. Reddy's Laboratories Limited's revenue grew from INR 10.9B in 2001 to INR 335.9B in 2026 (2972.1% over 25 years). Earnings per share grew from INR 25.17 in 2014 to INR 67.79 in 2025 (169.3%). Revenue compound annual growth rate: 5-year CAGR of 12.1%, 10-year CAGR of 8.1%, 20-year CAGR of 14.0%.
Total Revenue (Indian Rupees)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ₹980.44B
- Implied Share Price
- ₹1177.00
- Enterprise Value
- ₹978.80B
- Revenue (TTM)
- ₹331.19B
- EBITDA
- ₹54.67B
- Profit Margin
- 10.00%
- Trailing P/E
- 29.76
- Forward P/E
- 26.95
- Price/Book (MRQ)
- 2.57
- Price/Sales (TTM)
- 2.96
- EV/EBITDA
- 14.68
- EV/Revenue
- 2.96
- Dividend Yield
- 0.68%
- Book Value
- ₹460.31
- Free Cash Flow (FY2026)
- ₹30.51B
- Free Cash Flow Yield
- 3.11%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.